GSK-3β inhibitor 3

CAS No. 1448990-73-5

GSK-3β inhibitor 3( —— )

Catalog No. M34769 CAS No. 1448990-73-5

GSK-3β inhibitor 3 is a potent, selective, and irreversible covalent inhibitor of glycogen synthase kinase 3β (GSK-3β) with an IC50 of 6.6 μM, and can be used to study acute promyelocytic leukemia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 128 In Stock
5MG 188 In Stock
10MG 282 In Stock
25MG 513 In Stock
50MG 769 In Stock
100MG 1107 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK-3β inhibitor 3
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK-3β inhibitor 3 is a potent, selective, and irreversible covalent inhibitor of glycogen synthase kinase 3β (GSK-3β) with an IC50 of 6.6 μM, and can be used to study acute promyelocytic leukemia.
  • Description
    GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia.
  • In Vitro
    GSK-3β inhibitor 3 (compound 4-3) (100 μM) inhibits GSK-3α activity by 87.3%.GSK-3β inhibitor 3 (6.25-100 μM; 24-48 h) dose-dependently inhibits the growth of NB4 and NB4-R1 cells.GSK-3β inhibitor 3 (12.5-100 μM; 24 h) significantly increases the percentage of apoptosis in a dose-dependent pattern in NB4 and NB4-R1 cells.Cell Viability Assay Cell Line:NB4 and NB4-R1 cells Concentration:6.25, 12.5, 25, 50, 100 μM Incubation Time:24, 48 hours Result:Inhibited the cell viability, with IC50s of 19.56 μM and 26.42 μM in NB4 and NB4-R1 cells at 24 h, respectively.Had little cytotoxicity on human normal liver cells (LO2) and human umbilical vein endothelial cells (HUVECs).Apoptosis Analysis Cell Line:NB4 and NB4-R1 cells Concentration:12.5, 25, 50, 100 μM Incubation Time:24 hours Result:Induced cell apoptosis.
  • In Vivo
    GSK-3β inhibitor 3 (compound 4-3) (15 mg/kg/d; i.p. for 2 weeks) inhibits tumor growth of mice by 75.97% relative to vehicle control.GSK-3β inhibitor 3 (15 mg/kg; a single i.p.) shows long T1/2 of 14.2 h, high AUC values (AUClast=3503.42 ng/mL?h), and maximum concentration (Cmax=515 ng/mL) in mice.Animal Model:Balb/c female nude mice were injected leukemia cellsDosage:15 mg/kg/d Administration:I.p. for 2 weeks Result: Inhibited localized growth in NB4 cells.Had mild weight loss compared with control.Animal Model:Male ICR mice (30 g) Dosage:15 mg/kg (Pharmacokinetic Analysis) Administration:A single i.p.Result:T1/2=14.2 h; AUClast=3503.42 ng/mL?h; Cmax=515 ng/mL.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | GSK-3
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1448990-73-5
  • Formula Weight
    327.37
  • Molecular Formula
    C18H14FNO2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (763.66 mM; Ultrasonic )
  • SMILES
    Fc1ccc(cc1)C1CC(=O)N(C(=O)C=C)c2ccccc2S1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhang P, et, al. Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia. J Med Chem. 2021 May 24.?
molnova catalog
related products
  • Imipramine

    Imipramine (Dimipressin) is an orally active Fascin1 inhibitor with antidepressant and antitumor activity.

  • Soyasapogenol B

    Soyasapogenol B has anti-cancer, hypocholesterolemic, anticomplementary, hepatoprotective effects, it inhibits proliferation of cultured Hep-G2.

  • LDCA

    LDCA is a double-hit metabolic regulator that exhibits potent anti-proliferative activity. lDCA competitively inhibits LDH-A enzyme activity, alters mitochondrial hyperpolarization and simultaneously subverts apoptosis.